admin

Pregabalin & Heart Failure Risk: What Every Clinician Should Keep in Mind Written By: Dr. Janhvi Ajmera When a Common Painkiller Raises Uncommon Concerns Medicine evolves with every publication. What we once considered safe can quickly shift under the weight of new data. A recent JAMA Network Open study is the latest reminder: pregabalin, widely prescribed for neuropathic pain and seizures, may significantly raise the risk of heart failure in older adults. Involving more than 240,000 Medicare beneficiaries aged 65–89 years with noncancer chronic pain, the study found that patients starting pregabalin faced a 48% higher risk of developing heart failure compared with those prescribed gabapentin. For patients with a prior history of cardiovascular disease, the risk jumped to 85%. It’s a potential practice-changing signal. Why This Matters Older adults often sit at the intersection of multiple vulnerabilities: chronic pain, diabetes, hypertension, and existing heart disease. For them, every new medication can tip the balance between stability and crisis. Pregabalin binds strongly to the α2δ calcium channel subunit, which may promote sodium and water retention. In a patient with compromised cardiac reserve, this can accelerate fluid overload and trigger heart failure. What begins as leg swelling or shortness of breath can escalate quickly into hospitalization. In other words, the very drug intended to relieve suffering may quietly add to it. Practical Takeaways for Clinicians Reconsider first-line choices: Gabapentin, though less potent, may be a safer alternative for older patients with cardiovascular risk. Start low, go slow: If pregabalin is required, use the lowest dose possible and reassess frequently. Monitor early warning signs: New edema, rapid weight gain, or shortness of breath should prompt immediate review. Explore non-drug therapies: Physical therapy, CBT, mindfulness, and integrative strategies like yoga and breathing practices, which can reduce dependency on high-risk medications. The Bigger Picture Pregabalin is not alone in this spotlight. Other widely used pain medications, including NSAIDs and COX-2 inhibitors, carry well-documented cardiovascular risks. In older adults juggling multiple prescriptions, the combined effect of polypharmacy can double or even triple cardiovascular events. This underscores a central truth: safe prescribing is not about the drug alone, it’s about the patient, their context, and evolving evidence. What Future Research Is Needed? Mechanistic: How does pregabalin trigger fluid retention and heart failure at the molecular and physiological level? Dose-response relationship: Is there a threshold dose at which CVD risks rise, and whether lower doses are safer for specific populations? Comparative safety: How does pregabalin’s risk profile compare to other commonly used agents for neuropathic pain, such as duloxetine or tricyclic antidepressants? Non-drug interventions: Can structured nonpharmacological strategies (yoga, mindfulness-based stress reduction, or CBT) reduce reliance on pregabalin in high-risk groups? Outcomes: Beyond Medicare data, what do international cohorts reveal about pregabalin’s long-term safety? Addressing these gaps is essential not only for clinical safety but also for guiding rational prescribing and future guidelines. FAQs on Pregabalin and Heart Failure Risk 1. Is pregabalin safe for all elderly patients? Not necessarily. Older adults, especially those with prior cardiovascular disease, appear at higher risk for heart failure when taking pregabalin. Risk-benefit assessment is crucial. 2. Should pregabalin be avoided altogether? No. Pregabalin still has a role, particularly in refractory neuropathic pain or seizure management. But clinicians should prescribe cautiously, monitor closely, and consider safer alternatives when possible. 3. How does pregabalin compare to gabapentin? Gabapentin was associated with a lower risk in this study. While less potent, it may be preferable for patients with high cardiovascular risk. 4. What signs should patients and providers watch for? Leg swelling, rapid weight gain, shortness of breath, and fatigue may indicate fluid overload. Early detection can prevent progression to heart failure. 5. Are there non-drug options for chronic pain? Yes. Cognitive behavioral therapy, physiotherapy, yoga, and mindfulness are increasingly validated as adjuncts to pain management, particularly in older populations. Final Word For clinicians, IMGs, and researchers, this study is a reminder that there are no “routine prescriptions” in medicine. Every drug is a double-edged sword, and for older adults, pregabalin may tip the scales toward harm. The takeaway is’nt panic, but perspective. Reassess your prescribing habits, remain vigilant, and let emerging evidence guide safer, more holistic care. Because at the heart of medicine, whether in practice or research, is a single question: Are we truly helping the patient in front of us? REFERENCE https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2837132#google_vignette  Dual Antiplatelet Therapy: One-Size Doesn’t Fit All After PCI Could a Gout Drug Protect Your Heart? How Colchicine Is Emerging as Cardiovascular Medicine ___________ _____________________________

Menopause Management: A Modern Clinical Roadmap Written By: Dr. Janhvi Ajmera Menopause is a universal milestone, but for many women, it doesn’t come quietly. Hot flashes, night sweats, disrupted sleep, and mood swings can turn daily life into a challenge and sometimes for years. For physicians, the task is clear but meticulous: how do we ease symptoms without exposing patients to unnecessary risks? A recent JAMA review reframes this conversation by offering a structured, evidence-backed approach. But clinical guidelines are only as powerful as the way we apply them. Let’s unpack what this means for real-world practice and research. Symptom Burden: More Than Just Hot Flashes Nearly 8 in 10 women report vasomotor symptoms (VMS). For many, it’s more than discomfort; sleep disruption fuels fatigue, mood instability, and cardiovascular risk factors. The clinical fork in the road is straightforward: Mild symptoms → tolerable, no significant impact → reassure and avoid overtreatment. Moderate to severe symptoms → interfering with daily life → treatment is justified, often transformative. It sounds simple, yet underdiagnosis and undertreatment are global challenges. The Safety Lens: First, Do No Harm Hormone therapy (HT) is not for everyone. Before prescribing, clinicians must screen for red flags: History of breast cancer or estrogen-sensitive tumors Liver disease or impaired liver function Previous stroke, myocardial infarction, or thromboembolic disease When contraindications are present, HT is off the table. When they’re absent, the door to therapy opens, but still with careful weighing of risks and benefits. Hormone Therapy: The Right Patient, The Right Window For the right candidate, HT can be life-changing. Best outcomes are seen in: Women under 60 years old Within 10 years of menopause onset Without elevated risk for breast cancer or cardiovascular disease Treatment choices include: Estrogen-only therapy (for women with hysterectomy) Estrogen plus progestogen or bazedoxifene (for women with an intact uterus) The guiding principle? Lowest effective dose, regularly reassessed. Route of administration (oral vs transdermal) should be personalized. Beyond Hormones: The Nonhormonal Toolkit Not all patients can or want to use HT. Fortunately, the nonhormonal armamentarium is growing, and clinical trial data are reassuring. Evidence-backed alternatives include: SNRIs/SSRIs (e.g., venlafaxine, desvenlafaxine, escitalopram) Lifestyle strategies: structured exercise, weight management, cooling techniques, mindfulness-based interventions For some, these are not just substitutes, they’re first-line solutions that respect safety and patient choice. Clinical Pearls for Physicians Individualize always — menopause is a shared physiology but a unique experience for every patient. Don’t under-treat — severe VMS can erode quality of life and exacerbate comorbidities if left unmanaged. Think long-term — revisit treatment regularly; menopause care is a continuum, not a one-time prescription. Research Horizons: Where Science Must Go For biomedical researchers, menopause care represents an under-explored frontier. Key unanswered questions include: The molecular mechanisms behind hot flashes and thermoregulation Precision biomarkers to predict who benefits most from HT Safer nonhormonal agents with fewer side effects Longitudinal outcomes of early vs delayed HT initiation This is where the next decade of translational science can directly transform millions of lives. Final Word Menopause isn’t a pathology, but poorly managed symptoms can feel like one. With evidence-based use of hormone therapy, nonhormonal alternatives, and personalized care, physicians can empower women to navigate this transition with strength rather than struggle. Science and compassion must walk hand in hand. Menopause care isn’t only about reducing symptoms; it’s also about restoring quality of life. REFERENCE: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2833235?resultClick=1  Dual Antiplatelet Therapy: One-Size Doesn’t Fit All After PCI Pregabalin & Heart Failure Risk: What Every Clinician Should Keep in Mind